Inventiva and Echosens collaborate to bring awareness to NASH and encourage screening for at-risk patients
French clinical stage biopharmaceutical company Inventiva has announced a collaboration with US-based high-technology company Echosens to bring attention to, and increase the testing for, non-alcoholic steatohepatitis (NASH).
NASH is a chronic and progressive metabolic liver disease characterised by fat accumulation and inflammation in the liver, which can lead to cirrhosis, liver cancer and, potentially, the need for a liver transplant. The global prevalence is expected to increase by 63% by 2030, meaning more patients will be at risk of developing advanced liver disease ‒ the risk being higher in people with NASH.
Inventiva and Echosens will bring FibroScan to ten communities most at risk of NASH in the US and Europe, allowing more people to be tested for NASH while spreading awareness of the disease.
Frédéric Cren, chairman, CEO and co-founder of Inventiva, stated: “On this 6th annual edition of International NASH Day, we are extremely proud to join forces with Echosens in this effort to increase both awareness and identification of patients at risk of developing NASH. A tremendous effort is still required to ensure that patients are not left undiagnosed and that they eventually receive the care that they need. We are delighted to combine our expertise in the development of potential therapies for NASH together with Echosens’ world-class know-how in NASH diagnosis, for this initiative that will shed further light on this disease and help screen and identify patients at risk of developing NASH.”
Dominique Legros, CEO of Echosens commented: “There is a pressing need for a broader adoption of non-invasive liver tests to increase the diagnosis rate and improve the care of people living with NASH. We, alongside with our partners, have a joint responsibility to shape a future where patients have access to easy diagnosis solutions and effective therapies. We are very proud to partner with Inventiva to launch initiatives facilitating screening of NASH and increasing awareness of this disease among patients, healthcare providers and other stakeholders.”
Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for …
The Phase 3 trial for Genfit’s drug elafibranor has failed to improve outcomes for patients …